menu
    • menu
    [{"orgOrder":0,"company":"GRI Bio","sponsor":"Aardvark Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Amphetamine Sulfate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GRI Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"Tablet, Immediate Release","sponsorNew":"GRI Bio \/ Aardvark Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"GRI Bio \/ Aardvark Therapeutics"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Altium Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.029999999999999999,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Altium Capital","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Altium Capital"},{"orgOrder":0,"company":"GRI Bio","sponsor":"NIHR Respiratory TRC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ NIHR Respiratory TRC","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ NIHR Respiratory TRC"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Vallon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Merger","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"GRI Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.029999999999999999,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ GRI Bio","highestDevelopmentStatusID":"6","companyTruncated":"GRI Bio \/ GRI Bio"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Vallon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Merger","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.029999999999999999,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ GRI Bio","highestDevelopmentStatusID":"6","companyTruncated":"GRI Bio \/ GRI Bio"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by GRI Bio

    Menu

    GRI Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GRI Bio Shows Anti-Fibrotic Trend for GRI-0621 in IPF Phase 2a Trial

                            Details : GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 08, 2025

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GRI Bio Drives Phase 2a Enrollment for GRI-0621 in IPF Treatment

                            Details : GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2025

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            GRI Bio Closes $5M Public Offering for Growth and Expansion

                            Details : The net procceds from the offering will used to advance the clinical development of GRI-0621 (tazarotene), which is being evaluated for idiopathic pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 02, 2025

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            GRI Bio Announces Pricing of $5.0 Million Public Offering

                            Details : The net procceds from the offering will used to advance the clinical development of GRI-0621 (tazarotene), which is being evaluated for idiopathic pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 01, 2025

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GRI Bio Reports Encouraging Results from Phase 2a of GRI-0621 in IPF

                            Details : GRI-0621 is the company’s small molecule RAR dual agonist that inhibits the activity of human Type 1 Invariant NKT. It is being evaluated for Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 01, 2025

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GRI Bio Receives Approval for Phase 2a Biomarker Study of GRI-0621 in Australia

                            Details : GRI-0621 is an RAR-βɣ inhibitor small molecule drug candidate, currently being evaluated for treating idiopathic pulmonary fibrosis via oral soft gel capsule.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 26, 2024

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            GRI Bio Announces Pricing of $4 Million Public Offering

                            Details : The net proceeds will advance GRI's product candidate GRI-0621 (tazarotene), a small molecule RAR-beta gamma dual agonist, which is being evaluated for the idiopathic pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 27, 2024

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF

                            Details : Tazarotene is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 26, 2024

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GRI Bio Gets MHRA Authorization for Phase 2a Biomarker Study in the U.K

                            Details : GRI-0621 is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells. It is being evaluated in the Phase II clinical trial studies for Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 04, 2024

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            GRI Bio

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Trea...

                            Details : GRI-0621 is an iNKT inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of idiopathic pulmonary fibrosis via oral soft gel capsule.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 05, 2023

                            Lead Product(s) : Tazarotene

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth